Zobrazeno 1 - 10
of 40
pro vyhledávání: '"Ichinosuke Hyodo"'
Autor:
Mitsuaki Hirose, Masashi Sato, Ichinosuke Hyodo, Mamiko Imanishi, Kenji Yamato, Akinori Sugaya, Xiaoxuan Wang, Toshikazu Moriwaki, Xiaochen Zhang, Shinji Endo, Yoshiyuki Yamamoto
Publikováno v:
Anticancer Research. 41:1475-1483
Background/aim The oncoproteins murine double minute (MDM) 2 and MDM4 inactivate tumor-suppressor protein p53. Their mutual relationship with the prognosis of gastric cancer (GC) remains unknown. Patients and methods Expression of MDM2, MDM4, and p53
Autor:
Narikazu Boku, Shigenori Kadowaki, Min Hee Ryu, Hiroki Hara, Ichinosuke Hyodo, Keun Wook Lee, Keisho Chin, Yoshinori Miyata, Sang Cheul Oh, Se Hoon Park, Masahiro Tsuda, Yung-Jue Bang, Norisuke Nakayama, Hyun Cheol Chung, Ik Joo Chung, Yoon-Koo Kang, Hideo Baba, Shuichi Hironaka, Hisashi Hosaka
Publikováno v:
The Lancet Oncology. 21:1045-1056
Summary Background S-1 plus leucovorin and oxaliplatin showed promising efficacy for treatment of advanced gastric cancer in a randomised phase 2 study. We aimed to evaluate the efficacy and safety of oral TAS-118 (S-1 plus leucovorin) and oxaliplati
Autor:
Hiroshi Katayama, Narikazu Boku, Kensei Yamaguchi, Tomohiro Nishina, Takeshi Sakamoto, Hiroki Hara, Shinichiro Nakamura, Masanori Terashima, Kohei Shitara, Takako Eguchi Nakajima, Ichinosuke Hyodo, Kei Muro, Junki Mizusawa, Katsunori Shinozaki
Publikováno v:
Gastric Cancer. 23:677-688
Oral fluoropyrimidine plus cisplatin is often not tolerated by patients with severe peritoneal metastases of gastric cancer. Combination of 5-fluorouracil (5-FU), l-leucovorin (l-LV), and paclitaxel (FLTAX) has promising activity for such patients. W
Autor:
Keisho Chin, Kensei Yamaguchi, Shuichi Hironaka, Wasaburo Koizumi, Naotoshi Sugimoto, Kenji Amagai, Yasumasa Niwa, Masahiro Gotoh, Tomohiro Nishina, Kazuhiro Nishikawa, Ken Shimada, Akihito Tsuji, Hirofumi Fujii, Hiroshi Imamura, Hisateru Yasui, Nozomu Fuse, Yasuhide Yamada, Ichinosuke Hyodo, Masahiro Tsuda, Hirofumi Yasui
Publikováno v:
Cancer Science
Previous studies have shown sex‐related differences in the incidence of adverse events following treatment with fluoropyrimidines, however the mechanism of this difference is unknown. We examined sex‐related differences in the safety of S‐1 plu
Autor:
Takahisa Watahiki, Shingo Sakashita, Toshikazu Moriwaki, Ichinosuke Hyodo, Takeshi Yamada, Yukako Hamano, Keii To
Publikováno v:
Internal Medicine
The standard chemotherapies for neuroendocrine tumors (NETs) are somatostatin analog (SSA) and targeted-agents for NET G1/G2 and platinum-based chemotherapy for neuroendocrine carcinoma (NEC), classified according to the WHO criteria of 2010. We repo
Autor:
Ichinosuke Hyodo, Tsuneo Mizui, Naoyuki Hasegawa, Yoshiki Komatsu, Kazunori Ishige, Kuniaki Fukuda, Masato Endo, Yoshiyuki Yamamoto, Masashi Sato, Yuji Mizokami, Suguru Hirose, Masaomi Nagase, Junji Hattori, Masamichi Yamaura, Hitomi Kawai
Publikováno v:
Internal Medicine
A 70-year-old woman was referred to our department due to a solitary mediastinal tumor which gradually grew near the site of anastomosis for 8 years after radical surgery of esophageal squamous cell carcinoma. It was difficult to distinguish the lymp
Autor:
Toshikazu Moriwaki, Chiaki Enami, Suguru Hirose, Yoshiyuki Yamamoto, Noriaki Sakamoto, Masamichi Yamaura, Daisuke Suganuma, Masashi Sato, Ichinosuke Hyodo, Takeshi Yamada, Hiroki Tajima
Publikováno v:
Int Cancer Conf J
A 63-year-old man had advanced poorly differentiated gastric adenocarcinoma with para-aortic lymph node metastases. No HER2 expression was observed in four endoscopic biopsies from the primary tumor. Tumors shrunk after S-1 with cisplatin treatment,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::873652f97e4453c8967e9017be5e5152
https://europepmc.org/articles/PMC7297895/
https://europepmc.org/articles/PMC7297895/
Autor:
Yuzo Matsushita, Eishi Baba, Yuji Negoro, Akira Nozaki, Shuichi Hironaka, Tomomi Kashiwada, Taito Esaki, Tatsuya Okuno, Hideki Shimodaira, Kazuhiro Yanagihara, Naotoshi Sugimoto, Masahide Ebi, Naohiro Okano, Mototsugu Shimokawa, Ichinosuke Hyodo, Hiroyuki Okuda, Akitaka Makiyama, Toshikazu Moriwaki, Takuya Honda, Narikazu Boku, Kei Muro, Takashi Tsuda, Akihito Tsuji, Shingo Tamura, Takeshi Kajiwara, Masaaki Noguchi, Junko Sugiyama, Shinya Ueda, Satoshi Otsu, Michitaka Nagase, Keiko Minashi, Koji Takeda, Takao Tamura, Daisuke Sakai, Kenji Kunieda
Publikováno v:
Gastric Cancer. 21:792-801
Background Fluoropyrimidine and platinum combination is the standard treatment for advanced or recurrent gastric cancer (AGC). However, fluoropyrimidine monotherapy is commonly used for elderly patients with AGC because of its good tolerability. Meth
Autor:
Shuichi Hironaka, Keisho Chin, Chikuma Hamada, Tomohiro Nishina, Hiroshi Imamura, Naotoshi Sugimoto, Kensei Yamaguchi, Hideaki Bando, Yasuhide Yamada, Kazuhiro Nishikawa, Akihito Tsuji, Kenji Amagai, Hisateru Yasui, Hirofumi Fujii, Kenji Ishido, Ken Shimada, Ichinosuke Hyodo, Yasumasa Niwa, Hiroto Miwa, Masahiro Tsuda, Hirofumi Yasui, Masahiro Gotoh
Publikováno v:
Gastric Cancer. 20:640-645
The association between progression type and survival has been reported in breast cancer, but remains unclear in advanced gastric cancer (AGC). Here, this association was assessed using data obtained from an earlier randomized phase III study demonst
Autor:
Chikuma Hamada, Hirofumi Yasui, Keisho Chin, Akihito Tsuji, Hiroshi Imamura, Satoshi Tanabe, Kenji Amagai, Kensei Yamaguchi, Hideaki Bando, Ichinosuke Hyodo, Tomohiro Nishina, Hisateru Yasui, Ken Shimada, Shuichi Hironaka, Kazuhiro Nishikawa, Hirofumi Fujii, Masahiro Tsuda, Yasuhide Yamada, Naotoshi Sugimoto, Hiroto Miwa, Masahiro Gotoh, Yasumasa Niwa
Publikováno v:
Gastric Cancer. 19:919-926
A randomized phase III study of Japanese patients with advanced gastric cancer, the G-SOX trial, revealed that S-1 and oxaliplatin (SOX) combination therapy was noninferior to S-1 and cisplatin (CS) combination therapy. However, it is unclear whether